Tenet Healthcare Corporation stocks have been trading up by 19.16 percent after strong earnings and guidance bolstered investor confidence.
Click Here for a Millionaire's POV on Trading THC
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Q2 2026 adjusted EPS of $6.12 crushed the $4.26 consensus on $5.63B revenue, driven by strong same-store growth, cost control, and higher-acuity focus.
- Management lifted FY26 guidance to $20.30–$21.69 EPS and $21.9B–$22.5B revenue, alongside a roughly $295M EBITDA and $225M free cash flow boost at the midpoint.
- Net income nearly tripled and adjusted EPS climbed 52%, powered by better hospital margins and ambulatory strength, even with payer-mix pressure and some non-recurring boosts.
- Tenet Healthcare expanded buybacks, adding $2B to its authorization after repurchasing $1.04B, leaving $2.13B in remaining capacity.
- Analysts at Wells Fargo, Barclays, Guggenheim, and BofA kept bullish ratings on THC, with price targets clustering around $230–$242 despite sector-wide Medicaid and payor-mix worries.
Live Update At 12:32:11 EDT: On Friday, July 24, 2026 Tenet Healthcare Corporation stock [NYSE: THC] is trending up by 19.16%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
THC is trading like a name with momentum and numbers to back it up. The daily chart shows Tenet Healthcare ripping from a close of $199.02 on 2026/07/23 to $237.16 on 2026/07/24, a powerful post‑earnings continuation after a big gap. That’s a roughly 19% two-day move off the prior week’s $187–$195 zone — real range expansion that active traders look for.
Intraday, THC opened at $235.01 and spiked to $246.82 before settling in the high $230s. The 5‑minute tape shows repeated pushes over $243–$245 with higher lows holding above $240 for most of the morning, signaling strong dip demand and shorts getting squeezed.
More Breaking News
- OII Stock Jumps As Oceaneering Crushes Q2 Earnings And Lifts Outlook
- Allegion (ALLE) Stock Climbs Ahead Of Q2 2026 Earnings Call
- Quest Diagnostics Stock Gains As Oncology Moves Impress Wall Street
- American Airlines Stock Downgraded As Capacity Risks Loom
Under the hood, Tenet Healthcare is not just a story stock. Revenue sits around $21.31B with EBIT margin at 18.6% and EBITDA margin at 22.8%, strong numbers for a hospital operator. A P/E near 9.2 and price-to-sales of 0.72 tell traders the market still prices THC like a cyclical, even though return on equity near 48% and free cash flow at about $1.46B paint a high-return, cash-rich profile. Debt is heavy, but interest coverage around 5.9x and a current ratio of 1.4 show it is manageable for now.
Why Traders Are Watching THC After This Earnings Shock
This Q2 from Tenet Healthcare is the kind of “shock and reset” print that can change how a stock trades for months. THC posted adjusted EPS of $6.12, not just ahead of the $4.26 consensus, but also up from $4.02 a year ago. Revenue of $5.63B beat the $5.44B Street view, and management said the strength came from same-facility revenue growth, better hospital margins, and solid ambulatory performance.
For active traders, that’s important context. THC is not squeezing higher on hype alone; it is grinding higher on real operating leverage. Tenet Healthcare has leaned into higher-acuity services and free cash flow, which is exactly where the market wants hospital names right now. When margins expand while revenue climbs, you get this kind of upside surprise.
The bigger story is forward-looking. THC raised FY26 EPS guidance to $20.30–$21.69 versus prior consensus of $17.85, and lifted revenue targets to $21.9B–$22.5B. Adjusted EBITDA is now about $295M higher at the midpoint, and free cash flow is guided roughly $225M higher. That tells traders management is not expecting this quarter to be a one-off.
On top of that, Tenet Healthcare added $2B to its buyback after already repurchasing $1.04B in the prior quarter, leaving $2.13B still authorized. For THC traders, that is a potential bid in the background on pullbacks, especially in a name with a P/E under 10 and strong cash generation. The caveat: some upside came from non-recurring items and payer-mix remains a risk, so chasing parabolic candles without a plan is dangerous.
Conclusion
Analyst reaction lines up with the tape. Wells Fargo bumped its Tenet Healthcare target to $231 and kept an Overweight rating, pointing to improving Medicare Advantage and Exchange trends. Barclays nudged its target to $240 and also stayed Overweight. Guggenheim trimmed its target to $242 from $252, and BofA cut to $230, yet both maintained Buy ratings, saying sector sentiment had likely already washed out after weaker read‑throughs from other hospital and MedTech names.
That mix matters for THC traders. The Street is acknowledging macro risks — Medicaid and payor mix, sector-wide multiple pressure — but still treating Tenet Healthcare as one of the stronger operators in a tough group. When you line that up with a low‑teens or single‑digit earnings multiple, faster earnings growth, and a multi‑billion-dollar buyback, you get the recipe for sustained interest on both breakouts and dips.
For newer traders, the key is to respect both the trend and the risk. THC just ran nearly $40 in two sessions; that’s opportunity and danger at the same time. As Tim Sykes likes to say, “The market rewards prepared traders, not hopeful gamblers.” As Tim Bohen, lead trainer with StocksToTrade says, “There’s a pattern in everything; you just have to stick around long enough to see it.” Tenet Healthcare is giving data-driven traders a clear story right now — strong earnings, raised guidance, heavy buybacks — but the edge still comes from doing the homework, watching the key levels, and cutting losses fast if the thesis breaks.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.